Perdagangan Teva Pharma Ind Adr Rep 1 - TEVA CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.09 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.030779% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.013666% | ||||||||
Waktu biaya inap | 22:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Teva Pharmaceutical Industries Ltd ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
Prev. Close* | 10.67 |
Open* | 10.66 |
1-Year Change* | 25.56% |
Day's Range* | 10.64 - 10.73 |
52 wk Range | 6.78-11.45 |
Average Volume (10 days) | 8.25M |
Average Volume (3 months) | 194.23M |
Market Cap | 11.79B |
P/E Ratio | -100.00K |
Shares Outstanding | 1.11B |
Revenue | 15.14B |
EPS | -1.17 |
Dividend (Yield %) | N/A |
Beta | 1.21 |
Next Earnings Date | Feb 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 6, 2023 | 10.68 | 0.00 | 0.00% | 10.68 | 10.74 | 10.61 |
Feb 3, 2023 | 10.67 | 0.16 | 1.52% | 10.51 | 10.76 | 10.51 |
Feb 2, 2023 | 10.66 | 0.09 | 0.85% | 10.57 | 10.68 | 10.47 |
Feb 1, 2023 | 10.56 | 0.11 | 1.05% | 10.45 | 10.64 | 10.35 |
Jan 31, 2023 | 10.39 | 0.18 | 1.76% | 10.21 | 10.67 | 10.21 |
Jan 30, 2023 | 10.21 | 0.07 | 0.69% | 10.14 | 10.36 | 10.05 |
Jan 27, 2023 | 10.24 | 0.10 | 0.99% | 10.14 | 10.48 | 10.14 |
Jan 26, 2023 | 10.23 | 0.09 | 0.89% | 10.14 | 10.27 | 10.07 |
Jan 25, 2023 | 10.15 | 0.11 | 1.10% | 10.04 | 10.19 | 10.02 |
Jan 24, 2023 | 10.05 | -0.16 | -1.57% | 10.21 | 10.32 | 10.05 |
Jan 23, 2023 | 10.33 | 0.02 | 0.19% | 10.31 | 10.43 | 10.20 |
Jan 20, 2023 | 10.21 | -0.30 | -2.85% | 10.51 | 10.59 | 10.21 |
Jan 19, 2023 | 10.47 | 0.00 | 0.00% | 10.47 | 10.62 | 10.23 |
Jan 18, 2023 | 10.80 | 0.00 | 0.00% | 10.80 | 10.90 | 10.68 |
Jan 17, 2023 | 10.95 | -0.15 | -1.35% | 11.10 | 11.21 | 10.92 |
Jan 13, 2023 | 11.18 | -0.01 | -0.09% | 11.19 | 11.27 | 10.94 |
Jan 12, 2023 | 11.26 | 0.19 | 1.72% | 11.07 | 11.41 | 11.02 |
Jan 11, 2023 | 10.96 | 0.02 | 0.18% | 10.94 | 11.14 | 10.82 |
Jan 10, 2023 | 10.88 | 0.06 | 0.55% | 10.82 | 11.01 | 10.75 |
Jan 9, 2023 | 10.78 | -0.05 | -0.46% | 10.83 | 11.19 | 10.58 |
Teva Pharma Ind Adr Rep 1 Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
Revenue | 21903 | 22385 | 18854 | 16887 | 16659 | 15878 |
Cost of Revenue, Total | 10250 | 11770 | 10558 | 9351 | 8870 | 8014 |
Gross Profit | 11653 | 10615 | 8296 | 7536 | 7789 | 7864 |
Total Operating Expense | 20631 | 39911 | 20537 | 17330 | 20231 | 14162 |
Selling/General/Admin. Expenses, Total | 4973 | 4637 | 4052 | 3667 | 3519 | 3402 |
Research & Development | 2077 | 1778 | 1213 | 1010 | 997 | 967 |
Unusual Expense (Income) | 3286 | 21520 | 4838 | 3191 | 6739 | 1721 |
Other Operating Expenses, Total | 45 | -3 | -286 | -28 | -20 | -41 |
Operating Income | 1272 | -17526 | -1683 | -443 | -3572 | 1716 |
Interest Income (Expense), Net Non-Operating | -446 | -856 | -894 | -825 | -833 | -988 |
Other, Net | -2 | 3 | -19 | 3 | -1 | -70 |
Net Income Before Taxes | 824 | -18379 | -2596 | -1265 | -4406 | 658 |
Net Income After Taxes | 303 | -17507 | -2304 | -987 | -4238 | 447 |
Minority Interest | 18 | 184 | 322 | 2 | 109 | -39 |
Equity In Affiliates | 8 | -3 | -71 | -13 | 138 | 9 |
Net Income Before Extra. Items | 329 | -17326 | -2053 | -998 | -3991 | 417 |
Total Extraordinary Items | 0 | 1061 | -97 | 0 | 0 | |
Net Income | 329 | -16265 | -2150 | -998 | -3991 | 417 |
Total Adjustments to Net Income | -261 | -260 | -249 | -1 | 1 | |
Income Available to Common Excl. Extra. Items | 68 | -17586 | -2302 | -999 | -3990 | 417 |
Income Available to Common Incl. Extra. Items | 68 | -16525 | -2399 | -999 | -3990 | 417 |
Dilution Adjustment | 0 | |||||
Diluted Net Income | 68 | -16525 | -2399 | -999 | -3990 | 417 |
Diluted Weighted Average Shares | 961 | 1016 | 1021 | 1091 | 1095 | 1107 |
Diluted EPS Excluding Extraordinary Items | 0.07076 | -17.3091 | -2.25465 | -0.91567 | -3.64384 | 0.37669 |
Dividends per Share - Common Stock Primary Issue | 1.36 | 0.85 | 0 | |||
Diluted Normalized EPS | 2.29537 | -3.51127 | 0.82537 | 0.98547 | 0.35648 | 1.43282 |
Depreciation / Amortization | 209 | 162 | 139 | 126 | 99 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 3982 | 3910 | 3887 | 4100 | 3661 |
Revenue | 3982 | 3910 | 3887 | 4100 | 3661 |
Cost of Revenue, Total | 2063 | 1987 | 1989 | 1975 | 1859 |
Gross Profit | 1919 | 1923 | 1898 | 2125 | 1802 |
Total Operating Expense | 3548 | 3328 | 3264 | 4022 | 4374 |
Selling/General/Admin. Expenses, Total | 848 | 832 | 864 | 858 | 819 |
Research & Development | 254 | 243 | 222 | 249 | 225 |
Depreciation / Amortization | 27 | 25 | 24 | 23 | 22 |
Unusual Expense (Income) | 360 | 247 | 183 | 893 | 1502 |
Other Operating Expenses, Total | -4 | -6 | -18 | 24 | -53 |
Operating Income | 434 | 582 | 623 | 78 | -713 |
Interest Income (Expense), Net Non-Operating | -381 | -254 | -254 | -170 | -238 |
Other, Net | 91 | -20 | 13 | -83 | -20 |
Net Income Before Taxes | 144 | 308 | 382 | -175 | -971 |
Net Income After Taxes | 82 | 210 | 306 | -151 | -973 |
Minority Interest | -7 | -14 | -11 | -7 | -3 |
Equity In Affiliates | 3 | 11 | -5 | 0 | 21 |
Net Income Before Extra. Items | 78 | 207 | 290 | -158 | -955 |
Net Income | 78 | 207 | 290 | -158 | -955 |
Total Adjustments to Net Income | -1 | 2 | -1 | ||
Income Available to Common Excl. Extra. Items | 77 | 207 | 292 | -159 | -955 |
Income Available to Common Incl. Extra. Items | 77 | 207 | 292 | -159 | -955 |
Diluted Net Income | 77 | 207 | 292 | -159 | -955 |
Diluted Weighted Average Shares | 1107 | 1109 | 1109 | 1102 | 1107 |
Diluted EPS Excluding Extraordinary Items | 0.06956 | 0.18665 | 0.2633 | -0.14428 | -0.86269 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.25474 | 0.33851 | 0.39548 | 0.38244 | 0.01924 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 17228 | 15382 | 13794 | 13464 | 13005 | 12573 |
Cash and Short Term Investments | 1667 | 977 | 1784 | 1975 | 2177 | 2165 |
Cash & Equivalents | 988 | 963 | 1782 | 1975 | 2177 | 2165 |
Short Term Investments | 679 | 14 | 2 | |||
Total Receivables, Net | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
Accounts Receivable - Trade, Net | 7523 | 7128 | 5822 | 5676 | 4581 | 4529 |
Total Inventory | 4954 | 4924 | 4731 | 4422 | 4403 | 3818 |
Prepaid Expenses | 1629 | 1100 | 899 | 870 | 945 | 1075 |
Other Current Assets, Total | 1455 | 1253 | 558 | 521 | 899 | 986 |
Total Assets | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
Property/Plant/Equipment, Total - Net | 8073 | 7673 | 6868 | 6950 | 6855 | 6477 |
Property/Plant/Equipment, Total - Gross | 11926 | 12178 | 11796 | 11864 | 11947 | 11718 |
Accumulated Depreciation, Total | -3853 | -4505 | -4928 | -4914 | -5092 | -5241 |
Goodwill, Net | 44409 | 28414 | 24917 | 24846 | 20624 | 20040 |
Intangibles, Net | 21487 | 17640 | 14005 | 11232 | 8923 | 7466 |
Other Long Term Assets, Total | 1860 | 1423 | 1038 | 978 | 1233 | 1110 |
Total Current Liabilities | 18488 | 17921 | 14322 | 13674 | 13164 | 11027 |
Accounts Payable | 2157 | 2069 | 1853 | 1718 | 1756 | 1686 |
Accrued Expenses | 4264 | 3563 | 2738 | 2680 | 2581 | 2880 |
Notes Payable/Short Term Debt | 2466 | 766 | 516 | 514 | 514 | 23 |
Current Port. of LT Debt/Capital Leases | 810 | 2880 | 1700 | 1831 | 2674 | 1403 |
Other Current Liabilities, Total | 8791 | 8643 | 7515 | 6931 | 5639 | 5035 |
Total Liabilities | 59720 | 53256 | 45976 | 43498 | 40614 | 37388 |
Total Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
Long Term Debt | 32522 | 28827 | 26691 | 24562 | 22731 | 21617 |
Deferred Income Tax | 5413 | 3277 | 2140 | 1096 | 964 | 784 |
Minority Interest | 1656 | 1386 | 1087 | 1091 | 1035 | 966 |
Other Liabilities, Total | 1641 | 1845 | 1736 | 3075 | 2720 | 2994 |
Total Equity | 33337 | 17359 | 14707 | 13972 | 10026 | 10278 |
Redeemable Preferred Stock | 3620 | 3631 | 0 | |||
Common Stock | 54 | 54 | 56 | 56 | 57 | 57 |
Additional Paid-In Capital | 23409 | 23479 | 27210 | 27312 | 27443 | 27561 |
Retained Earnings (Accumulated Deficit) | 13607 | -3803 | -5958 | -6956 | -10946 | -10529 |
Treasury Stock - Common | -4194 | -4149 | -4142 | -4128 | -4128 | -4128 |
Unrealized Gain (Loss) | -7 | -4 | 1 | 0 | 0 | 0 |
Other Equity, Total | -3152 | -1849 | -2460 | -2312 | -2400 | -2683 |
Total Liabilities & Shareholders’ Equity | 93057 | 70615 | 60683 | 57470 | 50640 | 47666 |
Total Common Shares Outstanding | 1014.99 | 1016.88 | 1089.39 | 1092.19 | 1096.51 | 1103.33 |
Total Preferred Shares Outstanding | 3.7 | 3.7 | 0 | 0 | 0 | |
Long Term Investments | 83 | 61 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 12401 | 12822 | 12154 | 12573 | 12451 |
Cash and Short Term Investments | 1743 | 2436 | 2045 | 2165 | 2175 |
Cash & Equivalents | 1743 | 2436 | 2045 | 2165 | 2175 |
Total Receivables, Net | 4572 | 4488 | 4046 | 4529 | 4253 |
Accounts Receivable - Trade, Net | 4572 | 4488 | 4046 | 4529 | 4253 |
Total Inventory | 4406 | 4362 | 4167 | 3818 | 4012 |
Prepaid Expenses | 942 | 1022 | 1066 | 1075 | 1064 |
Other Current Assets, Total | 738 | 514 | 830 | 986 | 947 |
Total Assets | 49004 | 49195 | 47851 | 47666 | 47059 |
Property/Plant/Equipment, Total - Net | 6641 | 6658 | 6547 | 6477 | 6396 |
Goodwill, Net | 20302 | 20421 | 20179 | 20040 | 19986 |
Intangibles, Net | 8445 | 8120 | 7832 | 7466 | 7116 |
Other Long Term Assets, Total | 1215 | 1174 | 1139 | 1110 | 1110 |
Total Current Liabilities | 12089 | 12691 | 11825 | 11027 | 11613 |
Accounts Payable | 1692 | 1551 | 1514 | 1686 | 1750 |
Accrued Expenses | 2377 | 2318 | 2590 | 2771 | 3078 |
Notes Payable/Short Term Debt | 23 | 23 | 323 | 23 | 23 |
Current Port. of LT Debt/Capital Leases | 2674 | 3507 | 2386 | 1403 | 2054 |
Other Current Liabilities, Total | 5323 | 5292 | 5012 | 5144 | 4708 |
Total Liabilities | 39004 | 38871 | 37384 | 37388 | 37715 |
Total Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
Long Term Debt | 22288 | 21602 | 21037 | 21617 | 20840 |
Deferred Income Tax | 991 | 932 | 910 | 784 | 666 |
Minority Interest | 975 | 987 | 984 | 966 | 916 |
Other Liabilities, Total | 2661 | 2659 | 2628 | 2994 | 3680 |
Total Equity | 10000 | 10324 | 10467 | 10278 | 9344 |
Common Stock | 57 | 57 | 57 | 57 | 57 |
Additional Paid-In Capital | 27474 | 27503 | 27529 | 27561 | 27587 |
Retained Earnings (Accumulated Deficit) | -10869 | -10662 | -10370 | -10529 | -11484 |
Treasury Stock - Common | -4128 | -4128 | -4128 | -4128 | -4128 |
Other Equity, Total | -2534 | -2446 | -2621 | -2683 | -2688 |
Total Liabilities & Shareholders’ Equity | 49004 | 49195 | 47851 | 47666 | 47059 |
Total Common Shares Outstanding | 1102.35 | 1102.89 | 1103.01 | 1103.33 | 1110.35 |
Total Preferred Shares Outstanding | 0 | ||||
Unrealized Gain (Loss) | 0 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 311 | -16449 | -2472 | -1000 | -4099 | 456 |
Cash From Operating Activities | 3890 | 2225 | 2446 | 748 | 1216 | 798 |
Cash From Operating Activities | 1524 | 2112 | 1842 | 1722 | 1557 | 1330 |
Deferred Taxes | 15 | -2331 | -837 | -985 | -696 | -120 |
Non-Cash Items | 2156 | 20538 | 5736 | 1907 | 6642 | 833 |
Cash Taxes Paid | 341 | 106 | 420 | 552 | 709 | 495 |
Cash Interest Paid | 290 | 795 | 815 | 840 | 846 | 913 |
Changes in Working Capital | -116 | -1645 | -1823 | -896 | -2188 | -1701 |
Cash From Investing Activities | -34405 | 3446 | 1866 | 1355 | 863 | 1523 |
Capital Expenditures | -901 | -874 | -651 | -525 | -578 | -562 |
Other Investing Cash Flow Items, Total | -33504 | 4320 | 2517 | 1880 | 1441 | 2085 |
Cash From Financing Activities | 25217 | -5750 | -3351 | -1926 | -1885 | -2172 |
Financing Cash Flow Items | -169 | -112 | -57 | -11 | -5 | -6 |
Total Cash Dividends Paid | -1558 | -1161 | -22 | -52 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 693 | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | 26251 | -4477 | -3272 | -1863 | -1880 | -2166 |
Foreign Exchange Effects | -660 | 54 | -142 | 16 | 8 | -128 |
Net Change in Cash | -5958 | -25 | 819 | 193 | 202 | 21 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 84 | 306 | 608 | 456 | -952 |
Cash From Operating Activities | -405 | -187 | 342 | 798 | -49 |
Cash From Operating Activities | 376 | 681 | 1010 | 1330 | 323 |
Deferred Taxes | -11 | 5 | 13 | -120 | -175 |
Non-Cash Items | 222 | 500 | 592 | 833 | 196 |
Changes in Working Capital | -1076 | -1679 | -1881 | -1701 | 559 |
Cash From Investing Activities | 508 | 989 | 1277 | 1523 | 161 |
Capital Expenditures | -150 | -263 | -409 | -562 | -157 |
Other Investing Cash Flow Items, Total | 658 | 1252 | 1686 | 2085 | 318 |
Cash From Financing Activities | -493 | -494 | -1671 | -2172 | 2 |
Financing Cash Flow Items | -2 | -3 | -5 | -6 | 2 |
Issuance (Retirement) of Debt, Net | -491 | -491 | -1666 | -2166 | 0 |
Foreign Exchange Effects | -44 | -49 | -80 | -128 | -62 |
Net Change in Cash | -434 | 259 | -132 | 21 | 52 |
Total Cash Dividends Paid | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Capital Research Global Investors | Investment Advisor | 10.5524 | 117190328 | 24024045 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.5415 | 39329765 | 39329765 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.8455 | 31600577 | -827744 | 2022-09-30 | LOW |
Abrams Capital, L.L.C. | Hedge Fund | 2.152 | 23899296 | -147060 | 2022-09-30 | |
Menora Mivtachim Insurance Ltd. | Insurance Company | 2.0987 | 23307560 | -3050 | 2022-09-30 | LOW |
Migdal Insurance and Financial Holdings Ltd | Insurance Company | 1.9447 | 21596560 | 216360 | 2022-12-31 | MED |
Phoenix Holdings Ltd | Holding Company | 1.8757 | 20831080 | 2301291 | 2022-09-30 | MED |
Clal Insurance Enterprises Holdings Ltd. | Investment Advisor | 1.7475 | 19406766 | 444000 | 2022-09-30 | LOW |
Harel Insurance Investments and Financial Services Ltd | Investment Advisor | 1.3613 | 15118229 | 985502 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.3418 | 14901933 | 1055920 | 2022-09-30 | LOW |
EXOR Investments (UK) LLP | Investment Advisor | 1.0375 | 11522187 | 11522187 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.9613 | 10675231 | -7647 | 2022-09-30 | LOW |
Miller Value Partners, LLC | Investment Advisor | 0.8334 | 9254875 | -79715 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7338 | 8148857 | 126299 | 2022-09-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.7189 | 7983801 | 5844332 | 2022-09-30 | HIGH |
Beck, Mack & Oliver LLC | Investment Advisor | 0.6787 | 7536985 | 1072190 | 2022-09-30 | LOW |
Camber Capital Management LP | Hedge Fund | 0.6753 | 7500000 | 4750000 | 2022-09-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5973 | 6633114 | 314715 | 2022-09-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4259 | 4730246 | -881152 | 2022-09-30 | LOW |
Schweizerische Nationalbank | Bank and Trust | 0.4247 | 4716093 | 27700 | 2022-09-30 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group +485000+
Trader
65000+
Klien aktif per bulan
$48000000+
Volume investasi per bulan
$28000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Pharmaceuticals (NEC) |
5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 485.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com